Hyperactive WNT signaling is a potent cancer driver but clinical translation of WNT inhibitors has been hampered by on-target toxicities. WNT signaling can be constrained through inhibition of the PARP-family enzymes tankyrase 1 (TNKS1) and TNKS2; however, existing TNKS inhibitors suppress WNT signaling in both tumor a...
Jill Zimmerman, Brandon F. Malone, Kevan Chu et al.· Nature Chemical Biology· 1 citation
Loss of the orphan GPCR GPR52 in human breast cell lines leads to increased cell clustering, hybrid/partial EMT, and increased tumour burden in zebrafish, further expanding the understanding of mechanisms driving cancer progression and opening the door to novel therapeutic approaches.
Sarah Z. Hanif, Caleb Kutz, C. C. Au et al.· British Journal of Cancer· 0 citations
To define mutation-specific lineage reversion and tumor initiation, Ptf1a-tdTomato mice and multiple KRAS mutants are implemented across several genetic, pharmacologic, and inflammatory perturbations in vivo to deciphering mutation-specific oncogenic trajectories and directing the implementation of KRAS-directed therap...
A. Grimont, David Falvo, W. Sisso et al.· Developmental Cell· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.